RECRUITING Phase 2 ClinicalTrials.gov

Acute Effects of Cannabis on Cognition and Affect

Sponsor: Washington State University • ClinicalTrials.gov ID: NCT07296874

Registry updated: 2026-09-29

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study will examine how a moderate dose of THC affects mood and cognitive functioning in regular cannabis users. The study uses a double-blind, placebo-controlled, crossover design, meaning each participant will complete two sessions. Specifically, each participant will be given active cannabis (20 mg THC) in one session, and placebo in the other session. The order will be randomized across participants, so half will receive cannabis first, and the other half will receive placebo first. Ninety two adults who use cannabis at least weekly will be recruited from the local community. After an online screening survey, eligible participants will attend a laboratory visit where the participants will provide informed consent and complete saliva and urine drug tests to confirm recent abstinence from cannabis and absence of other drugs. Participants who pass screening will complete baseline questionnaires of cannabis use patterns, depression, anxiety, ADHD symptoms, emotion regulation, affect, and demographic information. Cannabis and placebo materials (obtained from NIDA) will be vaporized using a Volcano vaporizer device. Participants will inhale the vapor under supervision, and neither the participant nor the researcher assessing outcomes will know which product is administered. After vaping, participants will complete repeated mood ratings and a battery of cognitive tests assessing executive functions like planning, inhibition, working memory, and cognitive flexibility. The participants will then watch a nature video and report their feelings of awe and affect. At the end of each session, participants will remain in a supervised room with entertainment and snacks until at least four hours have passed since vaping and the participants report feeling sober. The participants will then return for a second session with the opposite study condition (THC or placebo) one week later. Both sessions follow the same procedures. Participants are fully debriefed after completing the study.

Interventions

THC 20mg (Drug)
20 mg THC delivered by vaporizing 0.17 g of 11.86% THC cannabis flower obtained from NIDA, using a Volcano vaporizer.
Placebo (Drug)
Placebo obtained from NIDA and vaporized using a Volcano vaporizer.

Eligibility criteria

Inclusion Criteria: * be 21 years of age or older * be fluent in English * use of cannabis at least once a week for at least one year * inhalation as their typical method of administration * be willing to abstain from cannabis on the day of their scheduled testing session Exclusion Criteria: * neurological conditions (e.g., neurodegenerative disorders, severe head injury, multiple concussions) * serious psychiatric conditions (e.g., psychosis, bipolar disorder) * family history of psychosis * intellectual disabilities or learning disorders (e.g., dyslexia) * chronic medical conditions that affect cognition or increase risk of cannabis use or exposure to cold water (e.g., heart disease, diabetes, peripheral neuropathy, history of fainting or seizures, fractures or wounds on both hands or wrists), * heart disease * BMI \> 34 * pregnant or lactating * use of illicit drugs in past 6 months * heavy use of alcohol (drinking \>4 drinks \>4 times per week) * nicotine/tobacco use * have experienced a severe adverse reaction to cannabis (e.g., panic attack, psychosis)

Conditions

Cannabis Use

Locations

Washington State University — Pullman, Washington, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment